GlassScriptPhysician profile
Nichelle Megowan
NPI 1326458993
$12,322.54
in general payments reported to CMS, 2019-2025
31 companies · $2,988 in 2025
The $2,988 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $674 · 2021: $975 · 2022: $2,318 · 2023: $2,198 · 2024: $2,789 · 2025: $2,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,332 · Travel and Lodging: $518 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,331.92 |
| Travel and Lodging | $517.77 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,643.12 | 2019-2025 | Rotapro, Avvigo Guidance System, Emerge Push |
| Abiomed | $1,897.99 | 2022-2025 | Impella |
| Abbott Laboratories | $1,822.40 | 2019-2025 | Coroflow, Mitraclip, Xience Skypoint |
| Shockwave Medical, INC | $1,331.29 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $645.68 | 2022-2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $397.85 | 2021-2025 | Lifevest |
| Amgen INC. | $365.59 | 2019-2022 | |
| Medtronic, INC. | $265.22 | 2021-2022 | |
| Pfizer INC. | $250.09 | 2020-2025 | |
| Endovascular Engineering INC. | $236.60 | 2024-2025 | Helo Thrombectomy System |
| Novartis Pharmaceuticals Corporation | $222.64 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $164.93 | 2023-2024 | Xarelto |
| Scpharmaceuticals INC. | $153.92 | 2024-2025 | |
| Cardiovascular Systems INC. | $120.20 | 2022 | |
| Cordis US Corp. | $120.08 | 2024 | Selution Slrpta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $114.42 | 2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $109.54 | 2023-2024 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $88.54 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $72.55 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $54.69 | 2022-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.53 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $35.35 | 2019 | |
| Invivyd INC | $31.36 | 2025 | Pemgarda |
| Altathera Pharmaceuticals LLC | $27.60 | 2024 | Sotalol Hydrochloride |
| Lexicon Pharmaceuticals, INC. | $26.13 | 2024 | |
| United Therapeutics Corporation | $23.45 | 2023 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $19.96 | 2019 | |
| Terumo Medical Corporation | $14.77 | 2025 | Angio-Seal, Tr Band |
| Chiesi USA, INC. | $13.05 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichelle Megowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.